Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pharmacologically directed ara-C therapy for refractory leukemia.

W Plunkett, S Iacoboni, E Estey

    Seminars in Oncology
    |June 1, 1985
    PubMed
    Summary

    This study explored optimizing chemotherapy for acute leukemia by adjusting cytosine arabinoside (ara-C) dosing. Higher cellular ara-C triphosphate (ara-CTP) levels correlated with remission, leading to new individualized dosing strategies.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Is there a need for morphologic exam to detect relapse in AML if multi-parameter flow cytometry is employed?

    Leukemia·2017
    Same author

    A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials.

    Leukemia·2017
    Same author

    How good are we at predicting the fate of someone with acute myeloid leukaemia?

    Leukemia·2017
    Same author

    Acute myeloid leukemia therapy and the chosen people.

    Leukemia·2016
    Same author

    A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials.

    Leukemia·2016
    Same author

    Prediction of CR following a second course of '7+3' in patients with newly diagnosed acute myeloid leukemia not in CR after a first course.

    Leukemia·2016

    Area of Science:

    • Oncology
    • Pharmacology
    • Hematology

    Background:

    • Refractory acute leukemia treatment remains challenging.
    • Cytosine arabinoside (ara-C) is a key chemotherapy agent.
    • Understanding ara-C pharmacodynamics is crucial for treatment optimization.

    Purpose of the Study:

    • To investigate the correlation between cellular ara-CTP levels and complete remission in acute leukemia patients.
    • To optimize ara-C chemotherapy by adjusting dosing strategies based on individual pharmacodynamics.
    • To evaluate a new individualized dosing approach for improved treatment outcomes.

    Main Methods:

    • Assessed cellular ara-CTP pharmacodynamics in circulating blasts of patients receiving high-dose ara-C.
    • Modified intermittent dosing intervals to increase minimum cellular ara-CTP levels.

    Related Experiment Videos

  • Developed and tested an individualized continuous infusion (CI) of ara-C based on initial test doses.

    • Main Results:

    • A strong correlation was observed between complete remission and cellular ara-CTP levels.
    • Shortening intermittent dosing intervals increased minimum ara-CTP levels but not response rates.
    • Preliminary results of individualized CI ara-C show increased response rates and altered toxicity profiles.

    Conclusions:

    • Cellular ara-CTP levels are a significant predictor of remission in acute leukemia.
    • Individualized, pharmacologically guided ara-C dosing shows promise for improving treatment efficacy.
    • Further clinical trials are necessary to confirm the effectiveness of the new approach.